124 related articles for article (PubMed ID: 22779686)
1. Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.
Je EM; An CH; Yoo NJ; Lee SH
APMIS; 2012 Aug; 120(8):635-9. PubMed ID: 22779686
[TBL] [Abstract][Full Text] [Related]
2. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
[TBL] [Abstract][Full Text] [Related]
3. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas.
Soung YH; Lee JW; Nam SW; Lee JY; Yoo NJ; Lee SH
Oncology; 2006; 70(4):285-9. PubMed ID: 17047397
[TBL] [Abstract][Full Text] [Related]
5. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.
Simi L; Pratesi N; Vignoli M; Sestini R; Cianchi F; Valanzano R; Nobili S; Mini E; Pazzagli M; Orlando C
Am J Clin Pathol; 2008 Aug; 130(2):247-53. PubMed ID: 18628094
[TBL] [Abstract][Full Text] [Related]
6. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
7. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
Li HT; Lu YY; An YX; Wang X; Zhao QC
Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations in histiocytic sarcoma identified by next generation sequencing.
Liu Q; Tomaszewicz K; Hutchinson L; Hornick JL; Woda B; Yu H
Virchows Arch; 2016 Aug; 469(2):233-41. PubMed ID: 27259537
[TBL] [Abstract][Full Text] [Related]
9. Mutational and expressional analyses of NRF2 and KEAP1 in sarcomas.
Je EM; An CH; Yoo NJ; Lee SH
Tumori; 2012; 98(4):510-5. PubMed ID: 23052169
[TBL] [Abstract][Full Text] [Related]
10. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
[TBL] [Abstract][Full Text] [Related]
11. Frequent PIK3CA-activating mutations in hidradenoma papilliferums.
Liau JY; Lan J; Hong JB; Tsai JH; Kuo KT; Chu CY; Sheen YS; Huang WC
Hum Pathol; 2016 Sep; 55():57-62. PubMed ID: 27184479
[TBL] [Abstract][Full Text] [Related]
12. PI3K/Akt pathway mutations in retinoblastoma.
Cohen Y; Merhavi-Shoham E; Avraham-Lubin BC; Savetsky M; Frenkel S; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5054-6. PubMed ID: 19420344
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
14. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
[TBL] [Abstract][Full Text] [Related]
15. Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai.
Wang YL; Dai X; Li YD; Cheng RX; Deng B; Geng XX; Zhang HJ
Genet Mol Res; 2015 Nov; 14(4):14840-6. PubMed ID: 26600545
[TBL] [Abstract][Full Text] [Related]
16. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
17. Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma.
Li C; Shen Y; Ren Y; Liu W; Li M; Liang W; Liu C; Li F
Hum Pathol; 2016 Sep; 55():143-50. PubMed ID: 27237367
[TBL] [Abstract][Full Text] [Related]
18. Oncogene alterations in endometrial carcinosarcomas.
Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
[TBL] [Abstract][Full Text] [Related]
19. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas.
Mousses S; McAuley L; Bell RS; Kandel R; Andrulis IL
Mod Pathol; 1996 Jan; 9(1):1-6. PubMed ID: 8821948
[TBL] [Abstract][Full Text] [Related]
20. [Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma].
Liu P; Li DJ; Qin HD; Zhang RH; Chen LZ; Zeng YX
Ai Zheng; 2007 Jan; 26(1):15-20. PubMed ID: 17222361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
